

**Tata Chemicals Limited**  
**Regd. Office: Bombay House, 24 Homi Mody Street, Mumbai - 400 001**  
**Statement of Consolidated Financial Results for the quarter and year ended 31 March, 2024**

(₹ in crore)

| Particulars  | Quarter ended 31 March, 2024 (Audited) (note 6) | Quarter ended 31 December, 2023 (Unaudited) | Quarter ended 31 March, 2023 (Audited) (note 6) | Year ended 31 March, 2024 (Audited) | Year ended 31 March, 2023 (Audited) |
|--|---|---|---|-------------------------------------|-------------------------------------|
| <b>1 Income</b>  |   |   |   |                                     |                                     |
| a) Revenue from operations   | 3,475   | 3,730                                       | 4,407   | 15,421                              | 16,789                              |
| b) Other income  | 114   | 38  | 75  | 286                                 | 218                                 |
| <b>Total income (1a + 1b)</b>  | <b>3,589</b>                                    | <b>3,768</b>                                | <b>4,482</b>                                    | <b>15,707</b>                       | <b>17,007</b>                       |
| <b>2 Expenses</b>  |   |   |   |                                     |                                     |
| a) Cost of materials consumed  | 625   | 649   | 630   | 2,710                               | 2,947                               |
| b) Purchases of stock-in-trade   | (16)  | 40  | 41  | 232                                 | 364                                 |
| c) Changes in inventories of finished goods, work-in-progress and stock-in-trade                               | (132)   | 8   | 189   | (241)                               | (28)                                |
| d) Employee benefits expense   | 479   | 469   | 457   | 1,860                               | 1,691                               |
| e) Power and fuel  | 633   | 705   | 734   | 2,673                               | 2,988                               |
| f) Freight and forwarding charges  | 660   | 556   | 587   | 2,268                               | 2,184                               |
| g) Finance costs   | 130   | 132   | 133   | 530                                 | 406                                 |
| h) Depreciation and amortisation expense   | 271   | 246   | 234   | 980                                 | 892                                 |
| i) Other expenses  | 783   | 761   | 804   | 3,072                               | 2,821                               |
| <b>Total expenses (2a to 2i)</b>   | <b>3,433</b>                                    | <b>3,566</b>                                | <b>3,809</b>                                    | <b>14,084</b>                       | <b>14,265</b>                       |
| <b>3 Profit before exceptional items, share of profit/(loss) of joint ventures and associate and tax (1-2)</b> | <b>156</b>                                      | <b>202</b>                                  | <b>673</b>                                      | <b>1,623</b>                        | <b>2,742</b>                        |
| 4 Exceptional items (net) (note 5)   | (963)   | -   | -   | (861)                               | -                                   |
| <b>5 Profit/(loss) before share of profit/(loss) of joint ventures and associate and tax (3+4)</b>             | <b>(807)</b>                                    | <b>202</b>                                  | <b>673</b>                                      | <b>762</b>                          | <b>2,742</b>                        |
| 6 Share of profit/(loss) of joint ventures and associate (net of tax)  | 11  | 60  | 13  | 68                                  | (2)                                 |
| <b>7 Profit/(loss) before tax (5+6)</b>  | <b>(796)</b>                                    | <b>262</b>                                  | <b>686</b>                                      | <b>830</b>                          | <b>2,740</b>                        |
| <b>8 Tax expenses</b>  |   |   |   |                                     |                                     |
| a) Current tax (note 4)  | 2   | 52  | 42  | 260                                 | 374                                 |
| b) Deferred tax  | 20  | 16  | (50)  | 121                                 | (86)                                |
| <b>Total tax expenses (8a + 8b)</b>  | <b>22</b>                                       | <b>68</b>                                   | <b>(8)</b>                                      | <b>381</b>                          | <b>288</b>                          |
| <b>9 Profit/(loss) from continuing operations after tax (7-8)</b>  | <b>(818)</b>                                    | <b>194</b>                                  | <b>694</b>                                      | <b>449</b>                          | <b>2,452</b>                        |
| 10 Share of loss of joint ventures from discontinued operations (net of tax) (note 3)                          | (23)  | -   | (2)   | (14)                                | (18)                                |
| <b>11 Loss from discontinued operations after tax</b>  | <b>(23)</b>                                     | <b>-</b>                                    | <b>(2)</b>                                      | <b>(14)</b>                         | <b>(18)</b>                         |
| <b>12 Profit/(loss) for the period (10+11)</b>   | <b>(841)</b>                                    | <b>194</b>                                  | <b>692</b>                                      | <b>435</b>                          | <b>2,434</b>                        |
| <b>13 Other comprehensive income ('OCI') - gain/(loss)</b>   |   |   |   |                                     |                                     |
| a) (i) Items that will not be reclassified to the Consolidated Statement of Profit and Loss                    |   |   |   |                                     |                                     |
| - Change in fair value of equity investments carried at fair value through OCI                                 | 567   | 876   | (276)   | 2,591                               | (82)                                |
| - Remeasurement of defined employee benefit plans  | 104   | (47)  | 120   | 47                                  | (52)                                |
| (ii) Income Tax relating to above items - charge   | 143   | 99  | (82)  | 375                                 | (37)                                |
| (iii) Share of other comprehensive credit /(charge) of joint ventures (net of tax)                             | 153   | 105   | 26  | 403                                 | (7)                                 |
| b) (i) Items that will be reclassified to the Consolidated Statement of Profit and Loss                        |   |   |   |                                     |                                     |
| - Effective portion of cash flow hedges  | 30  | (42)  | (239)   | 42                                  | (1,102)                             |
| - Changes in foreign currency translation reserve  | (6)   | 35  | (43)  | 108                                 | 437                                 |
| (ii) Income Tax relating to above items - charge   | 26  | (10)  | (43)  | 23                                  | (231)                               |
| (iii) Share of other comprehensive (charge) / credit of joint ventures (net of tax)                            | 18  | (5)   | 4   | 21                                  | 7                                   |
| <b>Total other comprehensive income - gain/(loss) (net of tax) (a(i-i+iii)+b(i-ii+iii))</b>                    | <b>697</b>                                      | <b>833</b>                                  | <b>(283)</b>                                    | <b>2,814</b>                        | <b>(531)</b>                        |
| <b>14 Total comprehensive income - gain/(loss) for the period (12+13)</b>                                      | <b>(144)</b>                                    | <b>1,027</b>                                | <b>409</b>                                      | <b>3,249</b>                        | <b>1,903</b>                        |
| <b>15 Profit/(loss) from continuing operations after tax (9)</b>   |   |   |   |                                     |                                     |
| Attributable to:   |   |   |   |                                     |                                     |
| Equity shareholders of the Company   | (827)   | 158   | 711   | 282                                 | 2,335                               |
| Non-controlling interests  | 9   | 36  | (17)  | 167                                 | 117                                 |
|  | <b>(818)</b>                                    | <b>194</b>                                  | <b>694</b>                                      | <b>449</b>                          | <b>2,452</b>                        |
| <b>16 Loss from discontinued operations after tax (11)</b>   |   |   |   |                                     |                                     |
| Attributable to:   |   |   |   |                                     |                                     |
| Equity shareholders of the Company   | (23)  | -   | (2)   | (14)                                | (18)                                |
| Non-controlling interests  | -   | -   | -   | -                                   | -                                   |
|  | <b>(23)</b>                                     | <b>-</b>                                    | <b>(2)</b>                                      | <b>(14)</b>                         | <b>(18)</b>                         |
| <b>17 Profit/(loss) for the period (12)</b>  |   |   |   |                                     |                                     |
| Attributable to:   |   |   |   |                                     |                                     |
| Equity shareholders of the Company   | (850)   | 158   | 709   | 268                                 | 2,317                               |
| Non-controlling interests  | 9   | 36  | (17)  | 167                                 | 117                                 |
|  | <b>(841)</b>                                    | <b>194</b>                                  | <b>692</b>                                      | <b>435</b>                          | <b>2,434</b>                        |
| <b>18 Other comprehensive income - gain/(loss) (net of tax) (13)</b>   |   |   |   |                                     |                                     |
| Attributable to:   |   |   |   |                                     |                                     |
| Equity shareholders of the Company   | 697   | 833   | (284)   | 2,814                               | (531)                               |
| Non-controlling interests  | -   | -   | 1   | -                                   | -                                   |
|  | <b>697</b>                                      | <b>833</b>                                  | <b>(283)</b>                                    | <b>2,814</b>                        | <b>(531)</b>                        |
| <b>19 Total comprehensive income - gain/(loss) for the period (14)</b>   |   |   |   |                                     |                                     |
| Attributable to:   |   |   |   |                                     |                                     |
| Equity shareholders of the Company   | (153)   | 991   | 425   | 3,082                               | 1,786                               |
| Non-controlling interests  | 9   | 36  | (16)  | 167                                 | 117                                 |
|  | <b>(144)</b>                                    | <b>1,027</b>                                | <b>409</b>                                      | <b>3,249</b>                        | <b>1,903</b>                        |
| <b>20 Paid-up equity share capital</b><br>(Face value : ₹ 10 per Share)  | 255   | 255   | 255   | 255                                 | 255                                 |
| <b>21 Other equity and Non-controlling interests</b>   |   |   |   | 22,859                              | 20,387                              |
| <b>22 Earnings per share for continuing operations (in ₹)</b><br>- Basic and Diluted                           | <b>(32.46)*</b>                                 | <b>6.20*</b>                                | <b>27.91*</b>                                   | <b>11.07</b>                        | <b>91.66</b>                        |
| <b>23 Earnings per share for discontinued operations (in ₹)</b><br>- Basic and Diluted                         | <b>(0.90)*</b>                                  | <b>-</b>                                    | <b>(0.08)*</b>                                  | <b>(0.55)</b>                       | <b>(0.71)</b>                       |
| <b>24 Earnings per share for continuing and discontinued operations (in ₹)</b><br>- Basic and Diluted          | <b>(33.36)*</b>                                 | <b>6.20*</b>                                | <b>27.83*</b>                                   | <b>10.52</b>                        | <b>90.95</b>                        |

\* Not annualised

See annexed segment information, balance sheet, cash flow and accompanying notes to the consolidated financial results

**Tata Chemicals Limited**  
**Consolidated Segment wise Revenue, Results, Assets and Liabilities**

(₹ in crore)

| Particulars   | Quarter ended<br>31<br>March,<br>2024<br>(Audited)<br>(note 6) | Quarter ended<br>31<br>December,<br>2023<br>(Unaudited) | Quarter ended<br>31<br>March,<br>2023<br>(Audited)<br>(note 6) | Year ended<br>31<br>March,<br>2024<br>(Audited) | Year ended<br>31<br>March,<br>2023<br>(Audited) |
|---|--|---|--|---|---|
| <b>1 Segment Revenue</b>  |  |   |  |   |   |
| a. Basic chemistry products   | 3,005  | 3,101   | 3,822  | 12,613  | 13,597  |
| b. Specialty products   | 471  | 629   | 589  | 2,811   | 3,198   |
|   | 3,476  | 3,730   | 4,411  | 15,424  | 16,795  |
| Less: Inter segment revenue   | 3  | 1   | 7  | 11  | 28  |
|   | 3,473  | 3,729   | 4,404  | 15,413  | 16,767  |
| Add: Unallocated  | 2  | 1   | 3  | 8   | 22  |
| <b>Total revenue from operations</b>  | <b>3,475</b>   | <b>3,730</b>  | <b>4,407</b>   | <b>15,421</b>                                   | <b>16,789</b>                                   |
| <b>2 Segment Results</b>  |  |   |  |   |   |
| a. Basic chemistry products (note 5(b))   | (682)  | 326   | 876  | 955   | 3,028   |
| b. Specialty products   | (39)   | 17  | (93)   | 149   | 91  |
| Total segment results   | (721)  | 343   | 783  | 1,104   | 3,119   |
| Less:   |  |   |  |   |   |
| (i) Finance costs   | 130  | 132   | 133  | 530   | 406   |
| (ii) Net unallocated expenditure/(income)(note 5(a))                                | (44)   | 9   | (23)   | (188)   | (29)  |
| <b>Profit/(loss) before share of profit of joint ventures and associate and tax</b> | <b>(807)</b>   | <b>202</b>  | <b>673</b>   | <b>762</b>                                      | <b>2,742</b>                                    |
| <b>3 Segment Assets</b>   |  |   |  |   |   |
| a. Basic chemistry products   | 21,722   | 22,467  | 22,177   | 21,722  | 22,177  |
| b. Specialty products   | 3,290  | 3,441   | 3,112  | 3,290   | 3,112   |
| Total segment assets  | 25,012   | 25,908  | 25,289   | 25,012  | 25,289  |
| Add: Unallocated  | 11,744   | 11,170  | 9,795  | 11,744  | 9,795   |
| <b>Total assets</b>   | <b>36,756</b>  | <b>37,078</b>   | <b>35,084</b>  | <b>36,756</b>                                   | <b>35,084</b>                                   |
| <b>4 Segment Liabilities</b>  |  |   |  |   |   |
| a. Basic chemistry products   | 4,146  | 3,984   | 4,494  | 4,146   | 4,494   |
| b. Specialty products   | 1,069  | 998   | 959  | 1,069   | 959   |
| Total segment liabilities   | 5,215  | 4,982   | 5,453  | 5,215   | 5,453   |
| Add: Unallocated  | 8,427  | 8,819   | 8,989  | 8,427   | 8,989   |
| <b>Total liabilities</b>  | <b>13,642</b>  | <b>13,801</b>   | <b>14,442</b>  | <b>13,642</b>                                   | <b>14,442</b>                                   |

**Tata Chemicals Limited**  
**Consolidated Balance Sheet as at 31 March, 2024**

(₹ in crore)

| Particulars   | As at<br>31<br>March,<br>2024<br>(Audited) | As at<br>31<br>March,<br>2023<br>(Audited) |
|---|--|--|
| <b>I. ASSETS</b>  |  |  |
| <b>(1) Non-current assets</b>                                 |  |  |
| (a) Property, plant and equipment                             | 6,786                                      | 6,367                                      |
| (b) Capital work-in-progress                                  | 2,165                                      | 2,351                                      |
| (c) Investment Property                                       | 52   | 52   |
| (d) Right of use assets                                       | 476  | 202  |
| (e) Goodwill  | 2,189                                      | 2,155                                      |
| (f) Other intangible assets                                   | 8,358                                      | 8,316                                      |
| (g) Intangible assets under development                       | 52   | 59   |
| (h) Investments in joint ventures and associate               | 1,491                                      | 1,136                                      |
| (i) Financial assets  |  |  |
| (i) Other investments   | 7,633                                      | 5,042                                      |
| (ii) Other financial assets                                   | 33   | 40   |
| (j) Deferred tax assets (net)                                 | 45   | 144  |
| (k) Advance tax assets (net)                                  | 859  | 767  |
| (l) Other non-current assets                                  | 250  | 289  |
| <b>Total non-current assets</b>                               | <b>30,389</b>                              | <b>26,920</b>                              |
| <b>(2) Current assets</b>                                     |  |  |
| (a) Inventories   | 2,524                                      | 2,532                                      |
| (b) Financial assets  |  |  |
| (i) Investments   | 615  | 1,270                                      |
| (ii) Trade receivables  | 1,900                                      | 2,627                                      |
| (iii) Cash and cash equivalents                               | 425  | 508  |
| (iv) Bank balances other than (iii) above                     | 220  | 157  |
| (v) Loans   | -  | 325  |
| (vi) Other financial assets                                   | 51   | 61   |
| (c) Current tax assets (net)                                  | 25   | -  |
| (d) Other current assets                                      | 598  | 680  |
|   | <b>6,358</b>                               | <b>8,160</b>                               |
| Assets classified as held for sale                            | 9  | 4  |
| <b>Total current assets</b>                                   | <b>6,367</b>                               | <b>8,164</b>                               |
| <b>Total assets</b>   | <b>36,756</b>                              | <b>35,084</b>                              |
| <b>II. EQUITY AND LIABILITIES</b>                             |  |  |
| <b>(1) Equity</b>   |  |  |
| (a) Equity share capital                                      | 255  | 255  |
| (b) Other equity  | 21,986                                     | 19,466                                     |
| <b>Equity attributable to equity share holders</b>            | <b>22,241</b>                              | <b>19,721</b>                              |
| Non-controlling interests                                     | 873  | 921  |
| <b>Total equity</b>   | <b>23,114</b>                              | <b>20,642</b>                              |
| <b>(2) Liabilities</b>  |  |  |
| <b>1 Non-current liabilities</b>                              |  |  |
| (a) Financial liabilities                                     |  |  |
| (i) Borrowings  | 2,898                                      | 5,540                                      |
| (ii) Lease liabilities  | 391  | 137  |
| (iii) Other financial liabilities                             | 58   | 48   |
| (b) Provisions  | 1,465                                      | 1,454                                      |
| (c) Deferred tax liabilities (net)                            | 2,375                                      | 1,935                                      |
| (d) Other non-current liabilities                             | 400  | 424  |
| <b>Total non-current liabilities</b>                          | <b>7,587</b>                               | <b>9,538</b>                               |
| <b>2 Current liabilities</b>                                  |  |  |
| (a) Financial liabilities                                     |  |  |
| (i) Borrowings  | 2,166                                      | 543  |
| (ii) Lease liabilities  | 108  | 76   |
| (iii) Trade payables  |  |  |
| - Outstanding dues of micro enterprises and small enterprises | 13   | 21   |
| - Outstanding dues of creditors other than above              | 2,356                                      | 2,576                                      |
| (iv) Other financial liabilities                              | 705  | 696  |
| (b) Other current liabilities                                 | 441  | 521  |
| (c) Provisions  | 233  | 352  |
| (d) Current tax liabilities (net)                             | 33   | 119  |
| <b>Total current liabilities</b>                              | <b>6,055</b>                               | <b>4,904</b>                               |
| <b>Total liabilities</b>                                      | <b>13,642</b>                              | <b>14,442</b>                              |
| <b>Total equity and liabilities</b>                           | <b>36,756</b>                              | <b>35,084</b>                              |

**Tata Chemicals Limited**  
**Consolidated Statement of Cash Flows for the year ended 31 March, 2024**

(₹ in crore)

|   | Year<br>ended<br>3<br>March,<br>2024<br>(Audited) | Year<br>ended<br>3<br>March,<br>2023<br>(Audited) |
|---|---|---|
| <b>A Cash flows from operating activities</b>   |   |   |
| Profit before tax from continuing operations  | 830   | 2,740   |
| Profit/(Loss) before tax from discontinued operations   | (14)  | (18)  |
|   | <b>816</b>  | <b>2,722</b>                                      |
| <b>Adjustments for :</b>  |   |   |
| Depreciation and amortisation expense   | 980   | 892   |
| Provision for impairment (note 5(b))  | 963   | -   |
| impairment of Intangible assets under development   | 9   | 30  |
| Finance costs   | 530   | 406   |
| Interest income   | (141)   | (75)  |
| Dividend income   | (49)  | (41)  |
| Share of (profit)/loss of joint ventures and associate  | (54)  | 20  |
| Net gain on sale of current investments   | (49)  | (57)  |
| Provision for employee benefits expense   | 67  | 82  |
| Provision for doubtful debts and advances/bad debts written off (net)   | 23  | 9   |
| (Reversal) of / provision for contingencies (net) (note 5(a))   | (82)  | 42  |
| Liabilities no longer required written back   | (1)   | (1)   |
| Foreign exchange loss (net)   | 47  | 30  |
| Loss/(profit) on assets sold or discarded (net)   | 12  | (2)   |
| <b>Operating profit before working capital changes</b>  | <b>3,071</b>                                      | <b>4,057</b>                                      |
| Adjustments for :   |   |   |
| Trade receivables, loans, other financial assets and other assets   | 811   | (509)   |
| Inventories   | (23)  | (237)   |
| Trade payables, other financial liabilities and other liabilities   | (456)   | 67  |
| <b>Cash generated from operations</b>   | <b>3,403</b>                                      | <b>3,378</b>                                      |
| Taxes paid (net of refund)  | (387)   | (407)   |
| <b>Net cash generated from operating activities</b>   | <b>3,016</b>                                      | <b>2,971</b>                                      |
| <b>B Cash flows from investing activities</b>   |   |   |
| Acquisition of property, plant and equipment and intangible assets (including capital work-in-progress and intangible assets under development) | (1,834)   | (1,578)   |
| Proceeds from sale of property, plant and equipment   | 11  | 34  |
| Proceeds from sale of other non-current investments   | -   | 150   |
| Investment in Non convertible Debentures (current investments)  | -   | (39)  |
| Purchase of current investments   | (3,830)   | (4,485)   |
| Purchase of non-current investments   | -   | (150)   |
| Proceeds from sale of current investments   | 4,494   | 4,636   |
| Proceeds from redemption of Non convertible Debentures (Current)  | 39  | -   |
| Bank balances not considered as cash and cash equivalents (net)   | (64)  | 391   |
| Loans - Inter-corporate deposit placed  | -   | (325)   |
| Loans - Inter-corporate deposit redeemed  | 325   | -   |
| Interest received   | 64  | 48  |
| Dividend received   | 185   | 132   |
| <b>Net cash used in investing activities</b>  | <b>(610)</b>                                      | <b>(1,186)</b>                                    |
| <b>C Cash flows from financing activities</b>   |   |   |
| Proceeds from borrowings  | 1,965   | 3,892   |
| Repayment of borrowings   | (3,114)   | (5,087)   |
| Repayment towards lease liabilities   | (122)   | (119)   |
| Finance costs paid  | (446)   | (344)   |
| Acquisition of non-controlling interests by the group   | (209)   | -   |
| Payment of Dividend to non-controlling interests  | (122)   | (100)   |
| Bank balances in dividend and restricted account  | 1   | 1   |
| Dividends paid  | (447)   | (319)   |
| <b>Net cash used in financing activities</b>  | <b>(2,494)</b>                                    | <b>(2,076)</b>                                    |
| <b>Net decrease in cash and cash equivalents</b>  | <b>(88)</b>                                       | <b>(291)</b>                                      |
| Cash and cash equivalents at the beginning of the period  | 508   | 762   |
| Exchange difference on translation of foreign currency cash and cash equivalents  | 5   | 37  |
| <b>Cash and cash equivalents at the end of the period</b>   | <b>425</b>  | <b>508</b>  |

## Tata Chemicals Limited

### Notes to the consolidated Financial Results:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 29 April, 2024. The same have been audited by the Statutory Auditors who have issued an unqualified opinion thereon.
- 2 The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company and its Indian subsidiaries will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- 3 Share of profit/(loss) of joint ventures from discontinued operations (net of tax) includes (loss)/profit from Tata Industries Limited (a joint venture of the Group).
- 4 Current tax for the quarter and year ended 31 March, 2024 is net of tax reversal relating to earlier years amounting to ₹ 67 crore and ₹ 85 crore respectively. Current tax for the quarter and year ended 31 March, 2023 is net of tax reversal relating to earlier years amounting to ₹ 19 crore and ₹ 35 crore respectively.
- 5 a) Exceptional gain for the year ended 31 March, 2024 amounting to ₹ 102 crore represents write-back of provisions made in earlier periods for an indirect tax matter upon settlement of dispute with concerned State Government authority.  
b) During the year ended 31 March, 2024, the Group has recognised a non-cash write down of assets aggregating to ₹ 963 crore which has been disclosed as an exceptional loss, in respect of United Kingdom - Soda ash and Bicarb operations ('UK Group operations').

The impairment is primarily due to unfavorable market conditions and reduced demand for Soda Ash in Europe and the persistently low pricing outlook in the jurisdiction based on which the cash flow projections have been revised downward.

This impairment of ₹ 963 crore represents the non-cash write down of the cash generating unit comprising property, plant and equipment of ₹ 821 crore, capital work-in-progress of ₹ 122 crore, Right-of-use assets of ₹ 4 crore and other assets (net) of ₹ 16 crore, relating to the UK Group operations.

- 6 Figures for the quarter ended 31 March, 2024 as reported in these consolidated financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.
- 7 The Board of Directors has recommended a final dividend of 150% (financial year 2022-23 : 175%) for the financial year 2023-24 i.e. ₹ 15.00 per share (financial year 2022-23: ₹ 17.50 per share) which is subject to approval of shareholders.
- 8 The standalone audited financial results of the Company are available for investors at [www.tatachemicals.com](http://www.tatachemicals.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

As per our report of even date attached  
For B S R & Co. LLP  
Chartered Accountants  
Firm's Registration No: 101248W/W - 100022

For and on behalf of  
TATA CHEMICALS LIMITED

Vijay Mathur  
Partner  
Membership No. 046476  
Place : Mumbai  
Date : 29 April, 2024

R. Mukundan  
Managing Director and CEO